The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Authors:
- Catherine ThieblemontCTCatherine Thieblemont
- Josette BriereJBJosette Briere
- Nicolas MounierNMNicolas Mounier
- Hans-Ullrich VoelkerHVHans-Ullrich Voelker
- Wendy CuccuiniWCWendy Cuccuini
- Edouard HirchaudEHEdouard Hirchaud
- Andreas RosenwaldARAndreas Rosenwald
- Andrew JackAJAndrew Jack
- Christer SundstromCSChrister Sundstrom
- Sergio CogliattiSCSergio Cogliatti
- Philippe TrougouboffPTPhilippe Trougouboff
- Ludmila BoudovaLBLudmila Boudova
- 1 November 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (31) , 4079-4087
Abstract
Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. Patients and Methods Among the 396 patients included on the trial, histologic material was available for a total of 249 patients at diagnosis (n = 189 patients) and/or at relapse (n = 147 patients), which included 87 matched pairs. The patient data were analyzed by immunochemistry for CD10, BCL6, MUM1, FOXP1, and BCL2 expression and by fluorescent in situ hybridization for BCL2, BCL6 and c-MYC breakpoints. The correlation with survival data was performed by using the log-rank test and the Cox model. Results Characteristics of immunophenotype and chromosomal abnormalities were statistically highly concordant in the matched biopsies. In univariate analysis, the presence of c-MYC gene rearrangement was the only parameter to be significantly correlated with a worse progression-free survival (PFS; P = .02) and a worse overall survival (P = .04). When treatment interaction was tested, the germinal center B (GCB) –like DLBCL that was based on the algorithm by Hans was significantly associated with a better PFS in the R-DHAP arm. In multivariate analysis, independent prognostic relevance was found for the GCB/non-GCB the Hans phenotype interaction treatment (P = .04), prior rituximab exposure (P = .0052), secondary age-adjusted International Prognostic Index (P = .039), and FoxP1 expression (P = .047). Confirmation was obtained by gene expression profiling in a subset of 39 patients. Conclusion COO remains a major and independent factor in relapsed/refractory DLBCL, with a better response to R-DHAP in GCB-like DLBCL. This needs confirmation by a prospective study.Keywords
This publication has 39 references indexed in Scilit:
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOPLaboratory Investigation, 2009
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screenProceedings of the National Academy of Sciences, 2008
- BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent MannerJournal of Biological Chemistry, 2008
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximabLeukemia, 2008
- Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphomaJournal of Experimental Medicine, 2007
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958